AQST at a glance
Aquestive Therapeutics, Inc. (AQST, SEC CIK 1398733) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on September 29, 2026 and Form 4 insider filings as recently as September 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Aquestive Therapeutics, Inc. (AQST) reported revenue of $44.5 million (down 22.6% from FY2024) and a net loss of $83.8 million. Diluted EPS was -$0.78.
- As of June 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Aquestive Therapeutics, Inc. (AQST) shares worth $101.1 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Barber Daniel on September 15, 2026 of 25,000 shares at $4.82 per share.
- In the last 90 days, AQST insiders reported 0 open-market purchases ($0) and 5 open-market sales ($374K) on Form 4, a net sale of $374K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $44.5M
- −22.6% vs prior year
- Insiders · 90 days
- 0 buys · 5 sells
- Net −$374K
- 13F holders
- 25 funds
- $101.1M · +0 vs prior quarter
- Latest 8-K
- Sep 29, 2026
- Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- Newly disclosed insider-trading risk: Rule 10b5-1 plans covering 132,992 shares adopted by the Chief Development and Commercial Officers
- Financial risk: May 12, 2026 Oaktree credit agreement secured by a security agreement
- Compliance risk: Omitted credit-agreement provisions may limit visibility into lender obligations
- Regulatory risk: Executive share sales depend on Rule 10b5-1(c) conditions and specified plan terms
AI summary of the AQST 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Richard J. Daly joins AQST’s Board October 14, 2026, as a Class I director serving through the 2028 annual meeting
- Board expands from seven to eight directors, with seven independent directors following the appointment
Item 7.01: Regulation FD Disclosure
- Investor presentation furnished under Regulation FD for institutional investor and analyst meetings
- Presentation content may be amended or updated through subsequent filings or other disclosures
Item 7.01: Regulation FD Disclosure
- Investor presentation furnished under Regulation FD for AQST’s H.C. Wainwright conference meetings
- Presentation dated September 14, 2026, targeting institutional investors and analysts
Item 8.01: Other Events
- Anaphylm NDA resubmitted to FDA for Type I allergic reactions, including anaphylaxis
- Regulatory milestone potentially restarts FDA review toward commercialization
AI summaries of AQST 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AQST
Don't miss the next AQST filing
- Alerts as it files. A push when AQST files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AQST, by share count.
- Ask anything. An AI agent that reads every AQST filing and answers with sources.
AQST alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Barber Daniel | Sell | Sep 15, 2026 | 25,000 | $4.82 |
| Korczynski Sherry | M | Sep 9, 2026 | 8,750 | $2.65 |
| Korczynski Sherry | M | Sep 9, 2026 | 8,750 | - |
| Boyd Peter E. | X | Sep 9, 2026 | 2,293 | - |
| Boyd Peter E. | X | Sep 9, 2026 | 2,293 | $0.96 |
| Korczynski Sherry | Sell | Sep 9, 2026 | 8,750 | $5.22 |
| Barber Daniel | X | Sep 8, 2026 | 91,743 | - |
| Barber Daniel | X | Sep 8, 2026 | 91,743 | $0.96 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $57.6M | $44.5M |
| Operating Income | - | -$30.8M | -$71.1M |
| Net Income | -$7.9M | -$44.1M | -$83.8M |
| Op. Margin | - | -53.5% | -159.5% |
| Net Margin | - | -76.7% | -188.1% |
| Balance Sheet | |||
| Total Assets | $57.4M | $101.4M | $160.4M |
| Equity | - | -$60.2M | -$33.7M |
| ROE | - | 73.4% | 248.9% |
| Per Share | |||
| EPS | $-0.13 | $-0.51 | $-0.78 |
| Cash Flow | |||
| Operating CF | - | -$35.8M | -$52.4M |
| CapEx | $995K | $159K | $562K |
Source: XBRL data in Aquestive Therapeutics, Inc. (AQST)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate AQST share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 25 | $101.1M |
| Q1 2026 | 25 | $98.8M |
| Q4 2025 | 24 | $175.0M |
| Q3 2025 | 23 | $119.7M |
| Q2 2025 | 21 | $68.4M |
| Q1 2025 | 18 | $34.8M |
| Q4 2024 | 16 | $36.1M |
| Q3 2024 | 14 | $35.6M |
- BlackRock+560.3K (+7%)
- State Street Corp+381.8K (+15%)
- AQR Capital Management+150.3K (+291%)
- Two Sigma Investments+141.8K (+12%)
- Vanguard Capital Management LLC+140.8K (+3%)
- Morgan Stanley−933.2K (-59%)
- Bank of America Corp−736.6K (-31%)
- Citadel Advisors LLC−113.0K (-20%)
- Raymond James Financial−5.2K (-9%)
- Renaissance Technologies LLC+416.2K
- Millennium Management−25.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 166 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AQST filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 29, 2026 | - | Analysis | - |
| 8-K | Sep 25, 2026 | - | Analysis | - |
| 8-K | Sep 17, 2026 | - | Analysis | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 11, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | May 19, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
AQST SEC filings: frequently asked questions
Are AQST insiders buying or selling?
In the last 90 days, Aquestive Therapeutics, Inc. (AQST) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $373,522 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold AQST stock?
As of June 30, 2026, the largest Aquestive Therapeutics, Inc. (AQST) holders among the 13F filers tracked by SignalX were BlackRock ($33.6 million), Vanguard Capital Management LLC ($19.1 million), State Street Corp ($12.2 million), Bank of America Corp ($6.9 million), Two Sigma Investments ($5.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was AQST's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Aquestive Therapeutics, Inc. (AQST) reported revenue of $44.5 million (down 22.6% from FY2024) and a net loss of $83.8 million. Diluted EPS was -$0.78. The figures come from the XBRL data in the 10-K.
What did AQST report in its latest 8-K?
Aquestive Therapeutics, Inc. (AQST) filed an 8-K on September 29, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Richard J. Daly joins AQST’s Board October 14, 2026, as a Class I director serving through the 2028 annual meeting.
What are the latest AQST SEC filings?
Aquestive Therapeutics, Inc. (AQST) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on September 29, 2026 and a Form 4 insider filing on September 16, 2026.
What is AQST's SEC CIK number?
Aquestive Therapeutics, Inc. (AQST)'s SEC Central Index Key (CIK) is 1398733. EDGAR lists every AQST filing under that number.
Ask anything about AQST
The research agent reads AQST's filings, financials, insider trades and 13F holders, then answers with sources.